Acquired hemolytic anemia
Chapter 3:Diseases of the blood and blood-forming organs
ICD-10 D59 is a billable code used to indicate a diagnosis of acquired hemolytic anemia.
Acquired hemolytic anemia (D59) refers to a group of conditions characterized by the premature destruction of red blood cells (RBCs) leading to anemia. This condition can arise from various factors, including autoimmune disorders, infections, certain medications, and exposure to toxins. Unlike hereditary forms of hemolytic anemia, acquired hemolytic anemia is not inherited but develops due to external factors. The destruction of RBCs can occur intravascularly (within blood vessels) or extravascularly (primarily in the spleen or liver). Symptoms may include fatigue, pallor, jaundice, dark urine, and splenomegaly. Diagnosis typically involves a combination of clinical evaluation, laboratory tests such as a complete blood count (CBC), reticulocyte count, and specific tests for hemolysis (e.g., haptoglobin, lactate dehydrogenase). Treatment focuses on addressing the underlying cause, which may involve immunosuppressive therapy, corticosteroids, or transfusions in severe cases. Understanding the etiology and pathophysiology of acquired hemolytic anemia is crucial for effective management and coding.
Detailed clinical history, laboratory results, and treatment plans.
Patients presenting with fatigue, jaundice, and elevated reticulocyte counts.
Ensure clear documentation of hemolytic processes and any autoimmune components.
Comprehensive patient history and physical examination findings.
Patients with unexplained anemia and signs of hemolysis.
Document any medications or infections that may contribute to hemolysis.
Used to evaluate anemia and hemolysis.
Document the reason for the test and results.
Hematologists may require more detailed lab interpretations.
Common causes include autoimmune disorders, infections, certain medications, and exposure to toxins. Each cause may require different management strategies.
